INCIDENCE, MITIGATION, AND MANAGEMENT OF NEUROLOGIC ADVERSE EVENTS IN PATIENTS WITH MULTIPLE MYELOMA TREATED WITH CILTACABTAGENE AUTOLEUCEL (CILTA-CEL) IN CARTITUDE-2

INCIDENCE, MITIGATION, AND MANAGEMENT OF NEUROLOGIC ADVERSE EVENTS IN PATIENTS WITH MULTIPLE MYELOMA TREATED WITH CILTACABTAGENE AUTOLEUCEL (CILTA-CEL) IN CARTITUDE-2

Objective: Cilta-cel (JNJ-68284528) is a chimeric antigen receptor T cell (CAR-T) therapy with two B-cell maturation antigen (BCMA)-targeting, single-domain antibodies designed to confer high avidity binding. CARTITUDE-2 (NCT04133636) is a phase 2, multicohort, open-label study assessing the efficac...

Full description

Bibliographic Details
Main Authors: H Einsele, S Parekh, D Madduri, B Santomasso, JG Pérez-Larraya, NWV Donk, B Arnulf, M Mateos, KC Braganca, H Varsos, MJ Carrasco-Alfonso, M Akram, N Lendvai, CC Jackson, Y Olyslager, E Zudaire, C Li, D Geng, A Jakubowiak, A Cohen
Format: Article
Language:English
Published: Elsevier 2021-10-01
Series:Hematology, Transfusion and Cell Therapy
Online Access:http://www.sciencedirect.com/science/article/pii/S2531137921005940

Internet

http://www.sciencedirect.com/science/article/pii/S2531137921005940

Similar Items